Plain-English translation of NCT07100730 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called TLX101-Tx, a targeted radiation therapy designed to deliver radiation directly to brain tumor cells. You would receive either this medication combined with a standard chemotherapy drug called lomustine, or lomustine alone. The goal is to see if adding this new treatment helps patients with recurrent glioblastoma live longer and improve their quality of life.
Glioblastoma is a serious brain cancer that often comes back even after initial treatment. When it recurs, treatment options are limited and outcomes are poor. This medication is being tested to see if it can better target and destroy recurring tumor cells when combined with standard chemotherapy.
You likely qualify if…
You likely don't qualify if…
You will be assigned to receive either the new medication plus chemotherapy, or chemotherapy alone. The study has two phases: the first part focuses on safety and finding the right dose, and the second part compares the combination treatment directly against standard chemotherapy. You will have regular clinic visits for imaging scans, blood tests, and monitoring of any side effects throughout the treatment period.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Australia
Austria